Document Detail

Decreased serum carnitine is independently correlated with increased tissue accumulation levels of advanced glycation end products in hemodialysis patients.
MedLine Citation:
PMID:  22804770     Owner:  NLM     Status:  Publisher    
SUMMARY AT A GLANCE: This study demonstrated decreased serum carnitine levels and elevated skin AGEs in hemodialysis patients, and provides a possible novel marker of cardiovascular outcomes in this group of patients. ABSTRACT: Background and Aims:   There is accumulating evidence that advanced glycation end products (AGEs) play a role in cardiovascular disease (CVD) in patients with hemodialysis (HD). Carnitine deficiency is frequently observed in HD patients, which may also contribute to CVD. In this study, we examined whether carnitine deficiency was independently associated with increased tissue accumulation levels of AGEs in HD patients. Methods:   One hundred twenty nine HD patients underwent determinations of blood chemistries including serum level of carnitine. Tissue AGE levels were evaluated by measuring skin autofluorescence with an AGE-reader. Results:   Serum carnitine levels were significantly lower, while skin AGE levels were significantly higher in HD patients compared with healthy control (p<0.001). In univariate analysis, β(2) -microglobulin (β(2) -MG) and carnitine (inversely) were correlated with skin AGE levels. Multiple stepwise regression analysis revealed that carnitine levels were one of the independent determinants of skin AGE levels (p=0.024). When β(2) -MG-adjusted skin AGE levels were stratified by serum carnitine levels, a statistical significance and dose-response relationship were observed (p=0.043). Furthermore, skin AGE levels were one of the independent determinants of serum carnitine levels as well (p=0.012). Conclusions:   The present study demonstrated that decreased carnitine levels were independently associated with increased skin AGE levels in HD patients. Since carnitine is reported to inhibit the formation of AGEs in vitro, our study suggests that supplementation of carnitine may be a therapeutic target for preventing the accumulation of tissue AGEs and subsequently reducing the risk of CVD in HD patients. © 2012 The Authors. Nephrology © 2012 Asian Pacific Society of Nephrology.
Takeki Adachi; Kei Fukami; Sho-Ichi Yamagishi; Yusuke Kaida; Ryotaro Ando; Kazuko Sakai; Hisashi Adachi; Aki Otsuka; Seiji Ueda; Kenzo Sugi; Seiya Okuda
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-7-13
Journal Detail:
Title:  Nephrology (Carlton, Vic.)     Volume:  -     ISSN:  1440-1797     ISO Abbreviation:  -     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-7-18     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9615568     Medline TA:  Nephrology (Carlton)     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2012 The Authors. Nephrology © 2012 Asian Pacific Society of Nephrology.
Division of Nephrology, Department of Medicine, Department of Pathophysiology and Therapeutics of Diabetic Complications, Department of Community Medicine, Kurume University School of Medicine, Kurume, Japan, Sugi Cardiovascular Hospital, Omuta, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Current status of gene delivery: spotlight on nanomaterial-polymer hybrids.
Next Document:  Student Learning: What Has Instruction Got to Do With It?